Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

(2021) Joel Simrén et al.   Alzheimers & Dementia

Advances in Brain Amyloid Imaging

(2021) Natasha Krishnadas et al.   SEMINARS IN NUCLEAR MEDICINE

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative

(2021) Anna Zettergren et al.   Alzheimers Research & Therapy

The Future Is P-Tau—Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests

(2021) Emily A. Largent et al.   JAMA Neurology

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

(2021) Alexis Moscoso et al.   JAMA Neurology

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

(2021) Pratishtha Chatterjee et al.   Translational Psychiatry

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease

(2021) Joyce R. Chong et al.   Alzheimers & Dementia

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

(2021) Niklas Mattsson‐Carlgren et al.   EMBO Molecular Medicine

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

(2021) Claudia Cicognola et al.   Alzheimers Research & Therapy

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression

(2021) Christopher Clark et al.   Alzheimers Research & Therapy

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease

(2021) Cécile Tissot et al.   Alzheimers Research & Therapy

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

A multicentre validation study of the diagnostic value of plasma neurofilament light

(2021) Nicholas J. Ashton et al.   Nature Communications

High burden of cerebral white matter lesion in 9 Asian cities

(2021) Bonnie Yin Ka Lam et al.   Scientific Reports

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

(2020) Alberto Benussi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

(2020) Martin Tolar et al.   Alzheimers Research & Therapy

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage

(2020) Breton M. Asken et al.   JOURNAL OF ALZHEIMERS DISEASE

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

(2020) Thomas K. Karikari et al.   Alzheimers & Dementia

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

(2020) Samantha Budd Haeberlein et al.   Alzheimers & Dementia

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease

(2020) Andréa L Benedet et al.   BRAIN

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

Head‐to‐head comparison of amplified plasmonic exosome Aβ42 platform and single‐molecule array immunoassay in a memory clinic cohort

(2020) Tomotaka Tanaka et al.   EUROPEAN JOURNAL OF NEUROLOGY

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

(2020) Steffi De Meyer et al.   Alzheimers Research & Therapy

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease

(2020) Oskar Hansson et al.   Annals of Clinical and Translational Neurology

Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition

(2019) Carine Z. J. Lim et al.   Nature Communications

Neurofilament light chain as a biomarker in neurological disorders

(2019) Lorenzo Gaetani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system

(2019) YoungSoo Kim et al.   Science Advances

Plasma and CSF neurofilament light

(2019) Michelle M. Mielke et al.   NEUROLOGY

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

2018 Alzheimer's disease facts and figures

(2018)   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Update on biomarkers for amyloid pathology in Alzheimer's disease

(2018) Nicholas J Ashton et al.   Biomarkers in Medicine

Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer’s Disease

(2018) Charlotte E. Teunissen et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease

(2018) Jonathan Vogelgsang et al.   EXPERIMENTAL BRAIN RESEARCH

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Current state of Alzheimer’s fluid biomarkers

(2018) José Luis Molinuevo et al.   ACTA NEUROPATHOLOGICA

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

(2018) Leslie M. Shaw et al.   Alzheimers & Dementia

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

(2018) Harald Hampel et al.   Nature Reviews Neurology

Serum neurofilament light in familial Alzheimer disease

(2017) Philip S.J. Weston et al.   NEUROLOGY

Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42

(2017) Seong Soo A. An et al.   Alzheimers Research & Therapy

Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

(2017) Min Jeong Wang et al.   Alzheimers Research & Therapy

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region

(2016) C. Chen et al.   JOURNAL OF INTERNAL MEDICINE

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease

(2014) Kai-Yuan Tzen et al.   ACS Chemical Neuroscience

The overlap between vascular disease and Alzheimer’s disease - lessons from pathology

(2014) Johannes Attems et al.   BMC Medicine

The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease

(2014) Josef Pannee et al.   NEUROSCIENCE LETTERS

Novel plasma biomarker surrogating cerebral amyloid deposition

(2014) Naoki KANEKO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease

(2013) Ming-Jang Chiu et al.   ACS Chemical Neuroscience

The future of blood-based biomarkers for Alzheimer's disease

(2013) Kim Henriksen et al.   Alzheimers & Dementia

Brain amyloid-β oligomers in ageing and Alzheimer’s disease

(2013) Sylvain E. Lesné et al.   BRAIN

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

(2013) Jon B Toledo et al.   Alzheimers Research & Therapy

Soluble Aβ oligomer production and toxicity

(2011) Megan E. Larson et al.   JOURNAL OF NEUROCHEMISTRY

Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans

(2011) Henrik Zetterberg et al.   PLoS One

Amyloid oligomers: formation and toxicity of Aβ oligomers

(2010) Masafumi Sakono et al.   FEBS Journal

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

(2008) Oskar Hansson et al.   NEUROBIOLOGY OF AGING